Palisade Bio Inc (PALI)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
expenditures have been increasing at the Palisade Bio Inc in the financial time-frame closing December 31 2022
Palisade Bio Inc announced fourth quarter of 2022 operating shortfall of $-3.848 million
Published 2023-03-23T17:19:52+00:00
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Trailing the big players in the Biotechnology & Pharmaceuticals industry, some lesser known companies are publishing their earnings. PALI mentioned it has realized operating shortfall of $-3.848 million, for the fourth quarter of 2022. The operating shortfall has contracted from $-3.78848 million, from the fourth quarter of 2021. But more crucially, the market participants are ruminating, if the Biotechnology & Pharmaceuticals company's will start to cite the top-line.
The prevailing difficulties with an evolving firm like PALI are if this entity has sufficient stamina in order successfully cultivate a prospective business strategy. A net deficit of $2.297 million, in the financial time-frame closing December 31 2022 posts a few problems at the stakeholders.
Palisade Bio Inc announced loss of $-14.55 million and revenue of $0.00 million in the financial year 2022.
Net loss per share has widen to $-16.53 from $-3.39 in the prior financial year, while by 0 % from $0.00 million a year prior.
Palisade Bio Inc is expected to report next financial recent numbers on August 14, 2023.